PT3100728T - Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos - Google Patents

Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos

Info

Publication number
PT3100728T
PT3100728T PT161762802T PT16176280T PT3100728T PT 3100728 T PT3100728 T PT 3100728T PT 161762802 T PT161762802 T PT 161762802T PT 16176280 T PT16176280 T PT 16176280T PT 3100728 T PT3100728 T PT 3100728T
Authority
PT
Portugal
Prior art keywords
prasugrel
making
methods
same
pharmaceutical compositions
Prior art date
Application number
PT161762802T
Other languages
English (en)
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of PT3100728T publication Critical patent/PT3100728T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
PT161762802T 2009-05-13 2010-05-13 Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos PT3100728T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17771809P 2009-05-13 2009-05-13

Publications (1)

Publication Number Publication Date
PT3100728T true PT3100728T (pt) 2020-02-21

Family

ID=43068670

Family Applications (1)

Application Number Title Priority Date Filing Date
PT161762802T PT3100728T (pt) 2009-05-13 2010-05-13 Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos

Country Status (13)

Country Link
US (4) US8236782B2 (pt)
EP (2) EP3100728B1 (pt)
JP (2) JP5808739B2 (pt)
KR (4) KR101743591B1 (pt)
CN (2) CN104606681B (pt)
CA (1) CA2761455C (pt)
DK (1) DK3100728T3 (pt)
ES (2) ES2588759T3 (pt)
HK (1) HK1210420A1 (pt)
HU (1) HUE047755T2 (pt)
PL (1) PL3100728T3 (pt)
PT (1) PT3100728T (pt)
WO (1) WO2010132711A1 (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160033792A (ko) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
PT3100728T (pt) 2009-05-13 2020-02-21 Cydex Pharmaceuticals Inc Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos
CN102232949A (zh) * 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
CN102139115B (zh) * 2011-03-30 2012-12-05 天津红日药业股份有限公司 阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
CN102755324B (zh) * 2011-04-25 2015-05-13 鲁南制药集团股份有限公司 一种含有普拉格雷和瑞舒伐他汀的药物组合物及其用途
CN102755319B (zh) * 2011-04-25 2015-05-13 鲁南制药集团股份有限公司 一种含有普拉格雷和卡维地洛的药物组合物及其用途
WO2013110567A1 (en) * 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
WO2013123254A1 (en) 2012-02-15 2013-08-22 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
WO2013130666A1 (en) 2012-02-28 2013-09-06 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
SG11201501743UA (en) * 2012-09-26 2015-04-29 Bristol Myers Squibb Co Apixaban liquid formulations
MY181829A (en) 2012-10-22 2021-01-08 Cydex Pharmaceuticals Inc Alkylated cyclodextrin compositions and processes for preparing and using the same
CN103848845B (zh) * 2012-12-07 2015-12-23 天津市汉康医药生物技术有限公司 普拉格雷倍半水合物及其制备方法
WO2014145443A2 (en) 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
WO2014161131A1 (en) * 2013-04-01 2014-10-09 Arissa Pharma PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
US9579257B2 (en) 2013-08-20 2017-02-28 Anutra Medical, Inc. Haptic feedback and audible output syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
CA2957535C (en) * 2014-08-07 2023-10-03 The General Hospital Corporation Stabilization of whole blood samples
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US9821075B2 (en) 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR102550497B1 (ko) * 2015-02-10 2023-07-03 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
DK3256138T3 (da) * 2015-11-25 2022-05-16 Axsome Therapeutics Inc Farmaceutiske sammensætninger omfattende meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR102627411B1 (ko) 2017-01-04 2024-01-18 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
CN108239185A (zh) * 2018-01-02 2018-07-03 昆明理工大学 一种奎尼丁与胺类环糊精的包合物
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11246851B2 (en) * 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
BR112021015467A2 (pt) 2019-02-06 2021-10-05 Axsome Therapeutics, Inc. Composições farmacêuticas compreendendo meloxicam
CN111714459B (zh) * 2020-06-18 2022-06-14 广州瑞尔医药科技有限公司 一种注射用舒更葡糖钠粉针剂及其制备方法
AU2021414212A1 (en) 2020-12-31 2023-07-20 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN112826944B (zh) * 2021-01-29 2023-08-15 台州职业技术学院 一种安立生坦包合物及其制备方法
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
WO2023222184A1 (en) * 2022-05-16 2023-11-23 Hyloris Developments Sa Aqueous ticagrelor solution, method of manufacturing and uses
WO2023222660A1 (en) * 2022-05-16 2023-11-23 Hyloris Developments Sa Aqueous ticagrelor solutions, method of manufacturing and uses
US12005118B2 (en) 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN116148397A (zh) * 2023-04-14 2023-05-23 黑龙江飞鹤乳业有限公司北京分公司 母乳低聚糖含量的检测方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US4927013A (en) 1989-04-12 1990-05-22 Eastman Kodak Company Package for storing and remixing two materials
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5241059A (en) * 1990-05-21 1993-08-31 Toppan Printing Co., Ltd. Cyclodextrin derivatives
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US5632275A (en) 1994-09-16 1997-05-27 Scribner-Browne Medical Design Incorporated Catheter lab table pad and method for using the same
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
ID23908A (id) 1997-06-05 2000-05-25 Lilly Co Eli Metode pengobatan dari penyakit trombosis
EP0986403B1 (en) * 1997-06-13 2003-11-12 Cydex Inc. Composition with extended shelf-life storage comprising cyclodextrin and drugs or prodrugs that decompose to water-insoluble components
ES2257795T3 (es) 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
FR2769313B1 (fr) 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
NZ505951A (en) 1998-02-23 2003-02-28 Cyclops Ehf A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
DE69926750T2 (de) 1998-06-17 2006-06-29 Bristol-Myers Squibb Co. Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
CN1210922A (zh) * 1998-10-22 1999-03-17 孙传经 超临界二氧化碳纱线染色工艺
US6509348B1 (en) 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
DE60134508D1 (de) 2000-07-06 2008-07-31 Daiichi Sankyo Co Ltd Säure-Additionssalze von Hydropyridinderivaten
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
DK1350511T3 (da) * 2000-12-25 2009-01-05 Daiichi Sankyo Co Ltd Medicinsk sammensætning indeholdende aspirin
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
CN1522159A (zh) 2001-06-29 2004-08-18 马克西根公司 干扰素配制品
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
US6767913B2 (en) 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
HUP0200438A3 (en) 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
CN1649616A (zh) 2002-03-01 2005-08-03 希龙公司 治疗缺血的方法和组合物
ITMI20020933A1 (it) 2002-05-03 2003-11-03 Danimite Dipharma S P A Procedimento per la sintesi di clopidogrel
CN100341589C (zh) 2002-05-24 2007-10-10 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
US6800759B2 (en) 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
CZ297472B6 (cs) 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
EP1545477A4 (en) 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
WO2004031143A2 (en) 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
BR0315198A (pt) 2002-10-09 2005-08-30 Insert Therapeutics Inc Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos
US20040115287A1 (en) 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
DE10305984A1 (de) 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004081015A1 (en) 2003-03-10 2004-09-23 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
US6858734B2 (en) 2003-04-23 2005-02-22 Rhodia Pharma Solutions Inc. Preparation of (S)-Clopidogrel and related compounds
EP1660183A2 (en) 2003-05-05 2006-05-31 Eli Lilly and Company Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4)
WO2005009412A1 (en) 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
KR20070005586A (ko) 2003-12-31 2007-01-10 사이덱스 인크 단위 용량 현탁액으로부터 제조된 술포알킬 에테르시클로덱스트린 및 코르티코스테로이드를 함유한 흡입용제형
US20070020196A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
SI21748A (sl) 2004-03-26 2005-10-31 Diagen D.O.O. Inkluzijski kompleksi klopidogrela in njegovih kislinskih adicijskih soli, postopek za njihovo pripravo, farmacevtski pripravki, ki vsebujejo te komplekse in njihova uporaba za zdravljenje tromboze
EP2386560A1 (en) 2004-04-09 2011-11-16 Hanmi Holdings Co., Ltd. Crystalline clopidogrel naphthalenesulfonate hydrate, method for preparing same and pharmaceutical composition containing same
MXPA06012777A (es) 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
US8128954B2 (en) 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
US20060047121A1 (en) 2004-09-01 2006-03-02 Sawant Kamlesh D Novel process for preparation of clopidogrel bisulfate polymorph - Form I
US20060154957A1 (en) 2004-09-21 2006-07-13 Nina Finkelstein Crystalline clopidogrel hydrobromide and processes for preparation thereof
US7446200B2 (en) 2004-10-04 2008-11-04 Usv, Ltd. Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I
EP1851231A2 (en) 2005-02-24 2007-11-07 Teva Pharmaceutical Industries Ltd Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20070003615A1 (en) 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
JP2008543853A (ja) 2005-06-17 2008-12-04 イーライ リリー アンド カンパニー プラスグレルのための薬剤投与計画
US20080200533A1 (en) 2005-07-04 2008-08-21 Ramu Krishnan Drug or Pharmaceutical Compounds and a Preparation Thereof
JP2009504737A (ja) * 2005-08-19 2009-02-05 イーライ リリー アンド カンパニー 脈管疾患の治療又は予防のためのpar−1/par−4阻害剤の使用
KR100783286B1 (ko) 2005-09-26 2007-12-06 주식회사종근당 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN100503647C (zh) 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
MX2009006037A (es) 2006-12-07 2009-06-16 Lilly Co Eli Un articulo de manufactura para prasugrel.
KR20080055356A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
KR20080055355A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
TWI417295B (zh) * 2007-03-02 2013-12-01 Daiichi Sankyo Co Ltd 高純度之普拉斯克列鹽酸鹽之製法
KR20160033792A (ko) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
WO2009018069A2 (en) 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
JP5137961B2 (ja) * 2007-10-22 2013-02-06 株式会社アドバンテスト 周波数変換装置および直交変調器
CN101456864B (zh) * 2007-12-11 2011-04-13 鲁南制药集团股份有限公司 普拉格雷硫酸盐、组合物及其制备方法
WO2010015144A1 (zh) * 2008-08-02 2010-02-11 鲁南制药集团股份有限公司 普拉格雷硫酸氢盐及其药物组合物和应用
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US9486431B2 (en) * 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
CN101390856B (zh) 2008-11-10 2011-04-20 重庆莱美药业股份有限公司 氯吡格雷的固体制剂及其制备方法
PT3100728T (pt) 2009-05-13 2020-02-21 Cydex Pharmaceuticals Inc Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos
CN102232949A (zh) * 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法

Also Published As

Publication number Publication date
KR20120026518A (ko) 2012-03-19
US20170007586A1 (en) 2017-01-12
EP2429291A1 (en) 2012-03-21
EP3100728B1 (en) 2019-11-20
ES2769949T3 (es) 2020-06-29
CN104606681A (zh) 2015-05-13
WO2010132711A1 (en) 2010-11-18
JP2012526849A (ja) 2012-11-01
CA2761455C (en) 2018-06-12
JP2016026174A (ja) 2016-02-12
US20100291056A1 (en) 2010-11-18
CN104606681B (zh) 2018-08-21
CA2761455A1 (en) 2010-11-18
PL3100728T3 (pl) 2020-05-18
US9399067B2 (en) 2016-07-26
KR20190071006A (ko) 2019-06-21
EP2429291A4 (en) 2013-06-05
JP5808739B2 (ja) 2015-11-10
US20130012534A1 (en) 2013-01-10
DK3100728T3 (da) 2020-02-17
KR101991367B1 (ko) 2019-06-21
EP3100728A1 (en) 2016-12-07
CN102625658A (zh) 2012-08-01
HK1210420A1 (en) 2016-04-22
US20150005341A1 (en) 2015-01-01
US8236782B2 (en) 2012-08-07
KR20170063988A (ko) 2017-06-08
JP5996063B2 (ja) 2016-09-21
KR101912709B1 (ko) 2018-10-30
ES2588759T3 (es) 2016-11-04
HUE047755T2 (hu) 2020-05-28
KR20180117205A (ko) 2018-10-26
US10111863B2 (en) 2018-10-30
US8835407B2 (en) 2014-09-16
KR101743591B1 (ko) 2017-06-20
CN102625658B (zh) 2015-01-28
EP2429291B1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
HK1210420A1 (en) Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
HK1250313A1 (zh) 穩定的藥物組合物和使用所述組合物的方法
IL217912A (en) History of 5-Amino-1-Benzimidazole-Pyrazole and Pharmaceutical Preparations Containing It
HK1164050A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
PT2413913T (pt) Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
EP2413901A4 (en) POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES
EP2506835A4 (en) COMPRESSIBLE COATED PHARMACEUTICAL COMPOSITION, TABLETS AND MANUFACTURING METHOD THEREFOR
IL215497A0 (en) Oxadiazile derivatives and pharmaceutical compositions containing them
PL2413912T3 (pl) Preparaty farmaceutyczne zawierające pochodne nitrokatecholu oraz metody ich wytwarzania
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
IL210163A0 (en) Pharmaceutical compositions comprising a complex of aminocyclohexane derivatives and cyclodextrin
ZA201200079B (en) Pharmaceutical compositions and solid forms
ZA201108458B (en) Nitrile derivatives and their pharmaceutical use and compositions
EP2320738A4 (en) SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
HK1174919A1 (en) Tricyclic derivatives and their pharmaceutical use and compositions
EP2503902A4 (en) SWEETENER COMPOSITIONS AND METHOD FOR THEIR MANUFACTURE
EP2484661A4 (en) 2,3-DIHYDRO-1H-INDEN-2-YL-UREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF
IL219018A (en) Radzolid Pharmaceuticals and Uses
HK1202865A1 (en) Tricyclic derivatives and their pharmaceutical use and compositions